Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J entered an agreement to acquire for a net price of approximately $924 million all outstanding shares of Neutrogena common stock through a $35.25 per share…
Neutrogena goes for $924 million at $35.25 per share; Moody's validated the deal, saying J&J could handle the borrowing and the companies' strengths appear…
Moody's said J&J could handle the borrowing, and the strengths of each company appear to be complementary; the $35.25 per share bid represented roughly a…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Johnson & Johnson acquired Neutrogena for approximately $924 million, or $35.25 per share in cash (roughly a 63% premium), through a cash tender offer and subsequent merger in 1994. The acquisition added the dermatologist-recommended skin-care brand to J&J's consumer-health portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Neutrogena (this deal) | 1994 | $924M | 48 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 1994 deals · Johnson & Johnson deals · Dermatology deals